MedTrace Logo

iLux Treatment for Meibomian Gland Dysfunction (MGD)

NCT03055650 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-11-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess changes in meibomian gland function and evaporative dry eye symptoms after treatment with the iLux medical device.

Conditions

  • Evaporative Dry Eye

Interventions

DEVICE

iLux 2020 System

Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands

Sponsors & Collaborators

  • Tear Film Innovations, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-07
Primary Completion
2016-02-18
Completion
2016-02-18
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03055650 on ClinicalTrials.gov